Compare Stocks: ACHV, GPCR, TARS, and ARQT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHV Achieve Life Sciences	$8.49 +2.2%	$6.93	$2.62 ▼ $8.64	$855.12M	2.25	1.44 million shs	874,073 shs
ARQT Arcutis Biotherapeutics	$23.90 +1.0%	$26.35	$16.21 ▼ $31.77	$2.97B	1.5	1.66 million shs	1.62 million shs
GPCR Structure Therapeutics	$47.34	$50.77	$19.50 ▼ $94.90	$3.30B	-1.45	721,795 shs	253,397 shs
TARS Tarsus Pharmaceuticals	$90.78 +9.1%	$66.01	$48.20 ▼ $91.53	$3.65B	0.54	743,029 shs	1.60 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHV Achieve Life Sciences	-2.00%	+1.59%	+28.44%	+61.99%	+190.56%
ARQT Arcutis Biotherapeutics	-0.80%	-4.87%	-9.10%	+11.45%	+48.43%
GPCR Structure Therapeutics	-0.96%	-3.82%	-4.63%	+25.97%	+140.18%
TARS Tarsus Pharmaceuticals	+0.54%	+15.70%	+36.16%	+40.37%	+44.16%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHV Achieve Life Sciences	$8.49 +2.2%	$6.93	$2.62 ▼ $8.64	$855.12M	2.25	1.44 million shs	874,073 shs
ARQT Arcutis Biotherapeutics	$23.90 +1.0%	$26.35	$16.21 ▼ $31.77	$2.97B	1.5	1.66 million shs	1.62 million shs
GPCR Structure Therapeutics	$47.34	$50.77	$19.50 ▼ $94.90	$3.30B	-1.45	721,795 shs	253,397 shs
TARS Tarsus Pharmaceuticals	$90.78 +9.1%	$66.01	$48.20 ▼ $91.53	$3.65B	0.54	743,029 shs	1.60 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHV Achieve Life Sciences	-2.00%	+1.59%	+28.44%	+61.99%	+190.56%
ARQT Arcutis Biotherapeutics	-0.80%	-4.87%	-9.10%	+11.45%	+48.43%
GPCR Structure Therapeutics	-0.96%	-3.82%	-4.63%	+25.97%	+140.18%
TARS Tarsus Pharmaceuticals	+0.54%	+15.70%	+36.16%	+40.37%	+44.16%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHV Achieve Life Sciences	3.00	Buy	$15.00	76.68% Upside
ARQT Arcutis Biotherapeutics	2.67	Moderate Buy	$35.57	48.83% Upside
GPCR Structure Therapeutics	2.89	Moderate Buy	$110.91	134.28% Upside
TARS Tarsus Pharmaceuticals	2.78	Moderate Buy	$90.50	-0.31% Downside

Current Analyst Ratings Breakdown

Latest ACHV, GPCR, TARS, and ARQT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2026	ARQT Arcutis Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/19/2026	ACHV Achieve Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/13/2026	ACHV Achieve Life Sciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$13.00
8/12/2026	ACHV Achieve Life Sciences	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$18.00
8/12/2026	TARS Tarsus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$97.00 ➝ $100.00
8/12/2026	ACHV Achieve Life Sciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/12/2026	ACHV Achieve Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
8/7/2026	GPCR Structure Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$111.00
8/7/2026	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/7/2026	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$100.00 ➝ $97.00
8/7/2026	GPCR Structure Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$113.00 ➝ $110.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	($0.14) per share	N/A
ARQT Arcutis Biotherapeutics	$376.07M	7.99	N/A	N/A	$1.75 per share	13.66
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$19.45 per share	N/A
TARS Tarsus Pharmaceuticals	$451.36M	8.83	N/A	N/A	$7.90 per share	11.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHV Achieve Life Sciences	-$54.65M	-$1.55	N/A	N/A	N/A	N/A	-511.12%	-82.35%	11/5/2026 (Estimated)
ARQT Arcutis Biotherapeutics	-$16.14M	$0.21	113.81	20.96	N/A	6.15%	15.05%	6.51%	10/27/2026 (Estimated)
GPCR Structure Therapeutics	-$141.20M	-$1.00	N/A	N/A	N/A	N/A	-25.56%	-24.31%	11/5/2026 (Estimated)
TARS Tarsus Pharmaceuticals	-$66.42M	-$1.09	N/A	159.26	N/A	-7.67%	-13.53%	-8.12%	11/3/2026 (Estimated)

Latest ACHV, GPCR, TARS, and ARQT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ACHV Achieve Life Sciences	-$0.1649	-$0.80	-$0.6351	-$0.80	N/A	N/A
8/6/2026	Q2 2026	GPCR Structure Therapeutics	-$0.39	-$0.49	-$0.10	-$0.49	N/A	N/A
8/6/2026	Q2 2026	TARS Tarsus Pharmaceuticals	-$0.1918	-$0.43	-$0.2382	-$0.43	$169.65 million	$173.91 million
8/5/2026	Q2 2026	ARQT Arcutis Biotherapeutics	$0.0551	$0.11	+$0.0549	$0.11	$118.85 million	$129.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	N/A
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHV Achieve Life Sciences	0.87	0.95	0.95
ARQT Arcutis Biotherapeutics	0.46	2.92	2.67
GPCR Structure Therapeutics	N/A	20.75	20.75
TARS Tarsus Pharmaceuticals	0.21	3.20	3.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHV Achieve Life Sciences	33.52%
ARQT Arcutis Biotherapeutics	N/A
GPCR Structure Therapeutics	91.78%
TARS Tarsus Pharmaceuticals	90.01%

Insider Ownership

Company	Insider Ownership
ACHV Achieve Life Sciences	1.80%
ARQT Arcutis Biotherapeutics	9.40%
GPCR Structure Therapeutics	5.50%
TARS Tarsus Pharmaceuticals	9.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHV Achieve Life Sciences	20	102.90 million	101.05 million	Optionable
ARQT Arcutis Biotherapeutics	150	125.69 million	113.88 million	Optionable
GPCR Structure Therapeutics	136	69.62 million	65.79 million	Optionable
TARS Tarsus Pharmaceuticals	50	43.88 million	39.65 million	Optionable

ACHV, GPCR, TARS, and ARQT Headlines

Recent News About These Companies

Tarsus Pharmaceuticals Shares Rise After Closing Alkeus Pharmaceuticals Acquisition

3 hours ago | marketscreener.comM

Tarsus Pharmaceuticals Closes Acquisition of Alkeus Pharmaceuticals

September 4 at 3:35 PM | finance.yahoo.com

Tarsus Pharmaceuticals Completes Alkeus Acquisition; Adds Phase 3 Stargardt Disease Program

September 4 at 3:35 PM | rttnews.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Hits New 52-Week High - Should You Buy?

September 4 at 2:19 PM | marketbeat.com

Tarsus Pharmaceuticals Completes Acquisition of Alkeus, Adds Gildeuretinol for Stargardt Disease to Pipeline

September 4 at 8:51 AM | quiverquant.comQ

Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care

September 4 at 8:38 AM | globenewswire.com

Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $339,829.86 in Stock

September 4 at 6:52 AM | insidertrades.com

114,458 Shares in Tarsus Pharmaceuticals, Inc. $TARS Bought by Bank of New York Mellon Corp

September 4 at 3:20 AM | marketbeat.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Elizabeth Yeu Lin Sells 4,601 Shares of Stock

September 3 at 5:07 PM | marketbeat.com

Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells 5,387 Shares

September 3 at 5:07 PM | marketbeat.com

Alkeus Announces Publication in JAMA Ophthalmology of Efficacy and Safety Results from the TEASE-1 Study of Gildeuretinol in Stargardt Disease

September 3 at 11:10 AM | globenewswire.com

The Manufacturers Life Insurance Company Takes Position in Tarsus Pharmaceuticals, Inc. $TARS

September 3 at 4:32 AM | marketbeat.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Trading 6.5% Higher - Should You Buy?

September 2 at 12:39 PM | marketbeat.com

Tarsus to Participate in Upcoming Investor Conferences

September 1 at 4:30 PM | globenewswire.com

Hsbc Holdings PLC Makes New $2.43 Million Investment in Tarsus Pharmaceuticals, Inc. $TARS

August 31, 2026 | marketbeat.com

Canada Pension Plan Investment Board Acquires Shares of 98,900 Tarsus Pharmaceuticals, Inc. $TARS

August 31, 2026 | marketbeat.com

Freestone Grove Partners LP Takes Position in Tarsus Pharmaceuticals, Inc. $TARS

August 29, 2026 | marketbeat.com

Jefferies Financial Group Inc. Acquires New Position in Tarsus Pharmaceuticals, Inc. $TARS

August 28, 2026 | marketbeat.com

90,969 Shares in Tarsus Pharmaceuticals, Inc. $TARS Purchased by Connor Clark & Lunn Investment Management Ltd.

August 28, 2026 | marketbeat.com

Seven Fleet Capital Management LP Has $7.91 Million Holdings in Tarsus Pharmaceuticals, Inc. $TARS

August 27, 2026 | marketbeat.com

Jupiter Topco LLC Invests $176.83 Million in Tarsus Pharmaceuticals, Inc. $TARS

August 27, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ACHV, GPCR, TARS, and ARQT Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

$8.49 +0.18 (+2.17%)

As of 04:00 PM Eastern

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Arcutis Biotherapeutics NASDAQ:ARQT

$23.90 +0.24 (+1.01%)

As of 04:00 PM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Structure Therapeutics NASDAQ:GPCR

$47.34 0.00 (0.00%)

As of 04:00 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Tarsus Pharmaceuticals NASDAQ:TARS

$90.78 +7.57 (+9.10%)

As of 04:00 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACHV, GPCR, TARS, and ARQT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACHV, GPCR, TARS, and ARQT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACHV, GPCR, TARS, and ARQT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ACHV, GPCR, TARS, and ARQT Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

Arcutis Biotherapeutics NASDAQ:ARQT

Structure Therapeutics NASDAQ:GPCR

Tarsus Pharmaceuticals NASDAQ:TARS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACHV, GPCR, TARS, and ARQT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACHV, GPCR, TARS, and ARQT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACHV, GPCR, TARS, and ARQT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ACHV, GPCR, TARS, and ARQT Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

Arcutis Biotherapeutics NASDAQ:ARQT

Structure Therapeutics NASDAQ:GPCR

Tarsus Pharmaceuticals NASDAQ:TARS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools